Many women notice that their digestion feels different in the years around menopause: more bloating, changeable bowel habits, or a flare-up of symptoms that had settled for years. For women living with inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, these shifts can feel confusing, particularly when it is unclear whether they reflect hormonal change, disease activity, or both.
What happens to digestion during menopause?
Menopause is the point at which periods stop permanently, usually confirmed after twelve months without a period, and it follows a gradual decline in the hormones oestrogen and progesterone. This hormonal transition, often called perimenopause when it is still underway, affects far more than reproductive tissue. Oestrogen receptors are present throughout the gut lining, the muscle layers that control movement, and even the community of bacteria living in the bowel (the gut microbiome). As oestrogen levels fall, many women experience slower gut transit, increased bloating, changes in stool consistency, and a general sense that their gut has become less predictable.
Why it matters for gut inflammation and IBD
For women with IBD, these hormonal changes do not occur in isolation. Oestrogen has a role in maintaining the integrity of the gut lining and in regulating immune activity in the bowel. When levels decline, some of the natural protective effects on the gut barrier and on inflammatory signalling (the chemical communication between immune cells that drives inflammation) may reduce. This does not mean menopause causes IBD to worsen for everyone, but it can shift the underlying environment in ways that make the gut more reactive to existing triggers.
Key mechanisms
Falling oestrogen and the gut microbiome
Oestrogen and the gut microbiome interact in both directions: certain gut bacteria help metabolise oestrogen, and oestrogen in turn supports a diverse, balanced microbial community. As oestrogen falls during menopause, microbial diversity can decrease, and this shift has been associated with increased gut permeability and low-grade inflammation. In IBD, where microbial balance is already altered, this additional change may contribute to symptom variability.
Gut barrier changes
The gut lining depends on tightly joined cells to prevent bacteria and their by-products from crossing into deeper tissue, a mechanism sometimes referred to as gut barrier function. Oestrogen appears to support the proteins that keep these junctions tight. Reduced oestrogen may weaken this barrier slightly, potentially increasing background immune activation. This is a gradual, cumulative process rather than a sudden event, and it is one reason gut symptoms can feel less stable during this life stage.
Motility and bile acid shifts
Oestrogen and progesterone influence how quickly food moves through the digestive tract. Their decline can slow transit, contributing to bloating, wind, and constipation, even in women whose IBD is otherwise well controlled. Hormonal change can also affect bile acid handling, which plays a part in fat digestion and stool consistency, occasionally contributing to looser stools in some women instead.
Immune signalling and symptom flares
Oestrogen has a modulating effect on several inflammatory pathways, including cytokines (signalling proteins used by immune cells). As hormone levels fluctuate and then settle at a lower baseline after menopause, some women report changes in symptom patterns, including new joint discomfort, fatigue, or gut sensitivity. These changes reflect shifting immune regulation rather than necessarily indicating active disease.
Symptoms are not always the same as inflammation
It is important to remember that menopausal symptoms and IBD symptoms can overlap considerably, both may involve bloating, fatigue, altered bowel habits, and abdominal discomfort. A change in symptoms during menopause does not automatically mean disease activity has increased. Objective markers, such as blood tests, faecal calprotectin (a marker of gut inflammation), or endoscopic assessment, remain the most reliable way to distinguish a genuine flare from hormonally driven changes. This is not something to manage through diet or lifestyle alone, and any new or persistent symptoms should be discussed with a gastroenterology team.
Practical Takeaways
- Track symptoms alongside menstrual changes if still perimenopausal, as patterns can help distinguish hormonal shifts from disease activity.
- Maintain consistent fibre and fluid intake to support motility, adjusting gradually rather than making sudden dietary changes.
- Prioritise regular meals and sleep, as both support hormonal stability and gut function.
- Discuss unexplained symptom changes with your IBD team rather than assuming they are “just menopause.”
- Ask your healthcare provider whether faecal calprotectin or other objective testing would help clarify whether symptoms reflect inflammation.
- If considering hormone replacement therapy, discuss this with both your GP and gastroenterology team, as it may have implications for IBD management.
Conclusion
Menopause brings genuine, biologically driven changes to digestion, and these changes can interact with the existing patterns of Crohn’s disease or ulcerative colitis. Understanding that falling oestrogen affects the gut microbiome, gut barrier, motility, and immune signalling can help make sense of symptoms that might otherwise feel unpredictable. The most important step is not to assume every new symptom reflects a flare, but to use objective assessment alongside symptom awareness. With good communication between patients and their care teams, this transition can be managed as part of a stable, long-term approach to gut health.
References
- Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: physiological and clinical implications. Maturitas. 2017;103:45-53. doi:10.1016/j.maturitas.2017.06.025
- Peters BA, Santoro N, Kaplan RC, Qi Q. Spotlight on the gut microbiome in menopause: current insights. Int J Womens Health. 2022;14:1059-1072. doi:10.2147/IJWH.S340491
- Kane SV, Reddy D. Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103(5):1193-1196. doi:10.1111/j.1572-0241.2007.01700.x
- Santoro N, Roeca C, Peters BA, Neal-Perry G. The menopause transition: signs, symptoms, and management options. J Clin Endocrinol Metab. 2021;106(1):1-15. doi:10.1210/clinem/dgaa764
- Flores R, Shi J, Fuhrman B, et al. Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study. J Transl Med. 2012;10:253. doi:10.1186/1479-5876-10-253
- Vemuri R, Sylvia KE, Klein SL, et al. The microgenderome revealed: sex differences in bidirectional interactions between the microbiota, hormones, immunity and disease susceptibility. Semin Immunopathol. 2019;41(2):265-275. doi:10.1007/s00281-018-0716-7
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.